2024
Clinical Outcomes in Breast Cancer Patients with Underlying Germline PALB2 Mutations Treated with Radiation
Shalaby A, Jan I, Ohri N, Yehia Z, Toppmeyer D, Haffty B. Clinical Outcomes in Breast Cancer Patients with Underlying Germline PALB2 Mutations Treated with Radiation. International Journal Of Radiation Oncology • Biology • Physics 2024, 120: e331-e332. DOI: 10.1016/j.ijrobp.2024.07.731.Peer-Reviewed Original ResearchBreast-conserving surgeryPALB2 variantsBreast cancer patientsInterpretations of pathogenicityClinical outcomesPathogenic variantsHYPO-RTBreast cancer patients treated with radiationCancer patients treated with radiationCancer patientsRisk of radiation toxicitySentinel lymph node dissectionPatients treated with radiationMedical recordsPALB2 pathogenic variantsContralateral breast cancerExternal beam radiationMedian tumor sizeLymph node dissectionSuppression of cancer developmentGrade 2 fibrosisRecurrence 4 monthsMultigene panel testingDNA double-strand break repairDouble-strand break repairThe Malignant Potential of Ovarian Steroid Cell Tumors Revisited
Fadare O, Fard E, Bhargava R, Desouki M, Hanley K, Ip P, Li J, Lu B, Medeiros F, Ng J, Parkash V, Pinto A, Quick C, Skala S, Tokuyama M, Turashvili G, Wei C, Xing D, Zheng W, Soong T, Howitt B. The Malignant Potential of Ovarian Steroid Cell Tumors Revisited. The American Journal Of Surgical Pathology 2024, 48: 570-580. PMID: 38512100, DOI: 10.1097/pas.0000000000002201.Peer-Reviewed Original ResearchSteroid cell tumorPredictor of patient outcomeDied of diseaseTumor hemorrhageTumor necrosisClinicopathological predictorsTumor sizeMalignant potentialCell tumorsAssociated with reduced recurrence-free survivalCases of steroid cell tumoursOvarian steroid cell tumorTumor size >4Median tumor sizeMicroscopic tumour necrosisMedian patient agePredictors of recurrenceRecurrence-free survivalMulti-institutional cohortPatient outcomesStage IA casesAssociated with recurrenceHigh-power fieldsLog-rank testUnivariate Cox model
2023
Does Preoperative MRI Reduce Positive Margins after Breast-Conserving Surgery?
Cairns A, Chagpar A, Dupont E, Levine E, Gass J, Chiba A, Ollila D, Howard-McNatt M. Does Preoperative MRI Reduce Positive Margins after Breast-Conserving Surgery? Annals Of Surgical Oncology 2023, 30: 6053-6058. PMID: 37505353, DOI: 10.1245/s10434-023-13884-8.Peer-Reviewed Original ResearchConceptsPreoperative magnetic resonance imagingMagnetic resonance imagingExtensive intraductal componentMargin statusPositive marginsTumor sizeTumor factorsMedian tumor sizeBreast conserving surgeryBreast cancer managementInvasive lobular histologyNeoadjuvant chemotherapyLobular histologyIntraductal componentMedian ageMulticenter trialPatient agePalpable tumorsPatient factorsShave marginsNegative marginsResultsA totalAssociated FactorsBreast cancerUS Centers
2021
Calcifying nested stromal–epithelial tumor: a clinicopathologic and molecular genetic study of eight cases highlighting metastatic potential and recurrent CTNNB1 and TERT promoter alterations
Papke D, Dong F, Zhang X, Kozielski R, Basturk O, Fletcher CDM, Zhao L. Calcifying nested stromal–epithelial tumor: a clinicopathologic and molecular genetic study of eight cases highlighting metastatic potential and recurrent CTNNB1 and TERT promoter alterations. Modern Pathology 2021, 34: 1696-1703. PMID: 33994539, DOI: 10.1038/s41379-021-00822-w.Peer-Reviewed Original ResearchConceptsStromal-epithelial tumorTERT promoter mutationsMetastatic diseaseCTNNB1 alterationsRare hepatic tumorRecurrent liver tumorsTERT promoter alterationsMedian tumor sizePromoter mutationsMolecular genetic featuresNuclear β-catenin expressionΒ-catenin expressionNeoadjuvant chemotherapyAbdominal metastasesLatter patientsLymphovascular invasionMedian ageLung metastasesTumor sizeHepatic tumorsNeuroendocrine markersEosinophilic cytoplasmLiver tumorsFibrous stromaTumor fibrosis
2020
TBCRC023: A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab Without Chemotherapy for 12 versus 24 Weeks in Patients with HER2-Positive Breast Cancer
Rimawi MF, Niravath P, Wang T, Rexer BN, Forero A, Wolff AC, Nanda R, Storniolo AM, Krop I, Goetz MP, Nangia JR, Jiralerspong S, Pavlick A, Veeraraghavan J, De Angelis C, Gutierrez C, Schiff R, Hilsenbeck SG, Osborne CK, Consortium O. TBCRC023: A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab Without Chemotherapy for 12 versus 24 Weeks in Patients with HER2-Positive Breast Cancer. Clinical Cancer Research 2020, 26: 821-827. PMID: 31662331, DOI: 10.1158/1078-0432.ccr-19-0851.Peer-Reviewed Original ResearchConceptsHER2-positive breast cancerPathologic complete responseDual anti-HER2 therapyAnti-HER2 therapyBreast cancerEstrogen receptorNeoadjuvant trialsPhase II neoadjuvant trialRandomized phase II trialHER2-positive breast tumorsDeescalation of therapyER-positive subgroupMedian tumor sizePhase II trialPhase II designAcneiform rashEvaluable patientsCommon toxicitiesII trialComplete responseMedian ageStudy treatmentTumor sizeExperimental armPatients
2019
HER2 heterogeneity as a predictor of response to neoadjuvant T-DM1 plus pertuzumab: Results from a prospective clinical trial.
Metzger Filho O, Viale G, Trippa L, Li T, Yardley D, Mayer I, Abramson V, Arteaga C, Spring L, Waks A, Janiszewska M, Wrabel E, Demeo M, Bardia A, King T, Polyak K, Winer E, Krop I. HER2 heterogeneity as a predictor of response to neoadjuvant T-DM1 plus pertuzumab: Results from a prospective clinical trial. Journal Of Clinical Oncology 2019, 37: 502-502. DOI: 10.1200/jco.2019.37.15_suppl.502.Peer-Reviewed Original ResearchPathologic complete responseER statusRCB 0T-DM1HER2 heterogeneitySignificant associationUltrasound-guided core biopsyRoutine pathology evaluationMedian tumor sizeProspective clinical trialsPredictors of responseAreas of tumorHigh rateCurative settingRCB-IIRCB-IIIPrimary endpointComplete responseHER2 positivityPathologic responseTherapy regimenEvaluable casesTumor sizeCore biopsyClinical trialsIntraductal Oncocytic Papillary Neoplasms
Wang T, Askan G, Adsay V, Allen P, Jarnagin W, Memis B, Sigel C, Seven I, Klimstra D, Basturk O. Intraductal Oncocytic Papillary Neoplasms. The American Journal Of Surgical Pathology 2019, 43: 656-661. PMID: 30986801, PMCID: PMC6467507, DOI: 10.1097/pas.0000000000001226.Peer-Reviewed Original ResearchConceptsIntraductal oncocytic papillary neoplasmInvasive carcinomaClinicopathological characteristicsOncocytic cellsMicroscopic fociOverall 10-year survivalHead of the pancreasConventional invasive carcinomaMedian tumor sizeRecurrence-free survivalInvasive carcinoma componentLymph node metastasisPresence of invasionFemale:male ratioFollow-up informationBenign ductsRare tumorCarcinoma componentIndolent behaviorIntraductal growthOverall survivalTumor sizeNode metastasisTumor typesPapillary neoplasm
2018
Comparing the long‐term outcomes among patients with stomach and small intestine gastrointestinal stromal tumors: An analysis of the National Cancer Database
Giuliano K, Ejaz A, Reames BN, Choi W, Sham J, Gage M, Johnston FM, Ahuja N. Comparing the long‐term outcomes among patients with stomach and small intestine gastrointestinal stromal tumors: An analysis of the National Cancer Database. Journal Of Surgical Oncology 2018, 118: 486-492. PMID: 30129672, DOI: 10.1002/jso.25172.Peer-Reviewed Original ResearchConceptsSmall intestine gastrointestinal stromal tumorGastrointestinal stromal tumorsNational Cancer DatabaseOverall survivalStromal tumorsTumor locationCancer DatabaseLarger median tumor sizeStomach gastrointestinal stromal tumorUnadjusted median overall survivalCox proportional hazards modelNational Oncology DatabaseMedian overall survivalMedian tumor sizeWorse prognostic featuresKaplan-Meier methodLong-term prognosisTumor-related factorsLong-term outcomesCases of stomachProportional hazards modelCommon sarcomaTotal patientsPrognostic featuresOncology database
2017
Role of axillary node dissection after mastectomy with positive sentinel nodes.
Park T, Thomas S, Greenup R, Hwang E. Role of axillary node dissection after mastectomy with positive sentinel nodes. Journal Of Clinical Oncology 2017, 35: 554-554. DOI: 10.1200/jco.2017.35.15_suppl.554.Peer-Reviewed Original ResearchAxillary lymph node dissectionPositive sentinel nodesAdjuvant radiationNode dissectionSentinel nodesTumor sizeRadiation treatmentComparable overall survivalLymph node dissectionMedian tumor sizeNational Cancer DatabaseStage IV diseaseAxillary node dissectionBreast conservation therapyHazard of deathAxillary lymphadenectomyPositive SLNZ11 trialCause mortalityEndocrine therapyNeoadjuvant chemotherapyPositive nodesNegative patientsOverall survivalSentinel lymph
2015
Retroperitoneal solitary fibrous tumor: surgery as first line therapy
Rajeev R, Patel M, Jayakrishnan T, Johnston F, Bedi M, Charlson J, Turaga K. Retroperitoneal solitary fibrous tumor: surgery as first line therapy. Clinical Sarcoma Research 2015, 5: 19. PMID: 26322223, PMCID: PMC4551387, DOI: 10.1186/s13569-015-0034-y.Peer-Reviewed Original ResearchNational Cancer DatabaseSurgical excisionTumor sizeRare spindle cell neoplasmMethodsThe National Cancer DatabaseBackgroundSolitary fibrous tumorMedian tumor sizeMargin negative resectionDied of diseaseSpindle cell neoplasmLow recurrence ratePeri-operative mortalityLong-term survivalSystematic review of published literatureSystematic reviewPrimary outcome measureIdentified 8 studiesMedian OSAdjuvant radiationNegative resectionMedian followSurgical resectionOverall survivalAdjuvant chemotherapyFibrous tumor
2014
Does three-dimensional intraoperative specimen imaging reduce the need for re-excision in breast cancer patients?
Chagpar A, Butler M, Killelea B, Horowitz N, Stavris K, Lannin D. Does three-dimensional intraoperative specimen imaging reduce the need for re-excision in breast cancer patients? Journal Of Clinical Oncology 2014, 32: 107-107. DOI: 10.1200/jco.2014.32.30_suppl.107.Peer-Reviewed Original ResearchMargin statusIntraoperative imagingFinal margin statusMedian tumor sizeBreast cancer patientsRe-excision ratesIntraoperative specimen radiographyCohort of interestIntraoperative marginsResidual tumorPartial mastectomyPositive marginsProspective studyTumor sizeCancer patientsInvasive cancerFurther excisionPathology resultsIntraoperative resectionPatientsDefinitive specimenSpecimen radiographyIntraoperative specimenSurgeonsPoorly Differentiated Neuroendocrine Carcinomas of the Pancreas
Basturk O, Tang L, Hruban R, Adsay V, Yang Z, Krasinskas A, Vakiani E, La Rosa S, Jang K, Frankel W, Liu X, Zhang L, Giordano T, Bellizzi A, Chen J, Shi C, Allen P, Reidy D, Wolfgang C, Saka B, Rezaee N, Deshpande V, Klimstra D. Poorly Differentiated Neuroendocrine Carcinomas of the Pancreas. The American Journal Of Surgical Pathology 2014, 38: 437-447. PMID: 24503751, PMCID: PMC3977000, DOI: 10.1097/pas.0000000000000169.Peer-Reviewed Original ResearchConceptsCell neuroendocrine carcinomaWell-differentiated neuroendocrine tumorsNeuroendocrine carcinomaSmall cell carcinomaAcinar cell carcinomaNeuroendocrine tumorsCell carcinomaFollow-upPoor-differentiated neuroendocrine carcinomasHead of the pancreasDistant metastatic diseaseMedian tumor sizeDied of diseaseMedian Follow-UpFollow-up informationMedian survivalMetastatic diseasePancreatic resectionTumor sizeAggressive neoplasmPatient ageClinicopathological featuresClinical featuresFrequent metastasisPoor survival
2012
Recurrence after microwave ablation of liver malignancies: a single institution experience
Groeschl R, Wong R, Quebbeman E, Tsai S, Turaga K, Pappas S, Christians K, Hohenwalter E, Tutton S, Rilling W, Gamblin T. Recurrence after microwave ablation of liver malignancies: a single institution experience. Hepato Pancreato Biliary 2012, 15: 365-371. PMID: 23458599, PMCID: PMC3633038, DOI: 10.1111/j.1477-2574.2012.00585.x.Peer-Reviewed Original ResearchConceptsRecurrence-free survivalMicrowave ablationLiver tumorsTumor histologyAssociated with time to recurrenceLocal control of liver tumorsMicrowave ablation of liver malignanciesPredictors of early recurrenceRetrospective single-institution reviewLocal controlPrimary tumor histologyMedian tumor sizeSingle-institution reviewPrimary tumor typeMedian Follow-UpTime to recurrenceConcomitant liver resectionPeri-operative morbidityMicrowave ablation proceduresColorectal metastasesMetastatic carcinoidMedian overallConsecutive patientsEarly recurrenceLiver resectionCost Comparison of Radiation Treatment Options After Lumpectomy for Breast Cancer
Greenup R, Camp M, Taghian A, Buckley J, Coopey S, Gadd M, Hughes K, Specht M, Smith B. Cost Comparison of Radiation Treatment Options After Lumpectomy for Breast Cancer. Annals Of Surgical Oncology 2012, 19: 3275-3281. PMID: 22851048, DOI: 10.1245/s10434-012-2546-5.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBrachytherapyBreast NeoplasmsCarcinoma, Ductal, BreastCarcinoma, Intraductal, NoninfiltratingCarcinoma, LobularCombined Modality TherapyCosts and Cost AnalysisFemaleFollow-Up StudiesHealth Care CostsHumansMastectomy, SegmentalMiddle AgedNeoplasm GradingNeoplasm InvasivenessPrognosisRetrospective StudiesConceptsWhole breast radiation therapyBreast cancerRT optionsExternal-beam partial breast irradiationLeukemia Group B 9343MethodsAn institutional review boardResultsMedian patient ageCurrent Procedural Terminology codesMedian tumor sizeInvasive ductal cancerSitu breast cancerPartial breast irradiationProcedural Terminology codesRadiation treatment optionsInstitutional review boardC-RTBackgroundRadiation therapyRT regimensBreast conservationDuctal cancerLobular cancerMixed histologyPatient ageRetrospective reviewTumor histologyCan primary tumor markers of cancer-initiating cells predict lymph node positivity in breast cancer patients?
Chagpar A, Neumeister V, Lannin D, Rimm D. Can primary tumor markers of cancer-initiating cells predict lymph node positivity in breast cancer patients? Journal Of Clinical Oncology 2012, 30: 1121-1121. DOI: 10.1200/jco.2012.30.15_suppl.1121.Peer-Reviewed Original ResearchBreast cancer patientsLN statusCancer patientsLymphovascular invasionTumor sizeTumor markersPositive LNsPoor prognosisMedian numberPrimary tumor markersMedian patient ageMedian tumor sizeLymph node positivityLN-positive patientsLymph node statusOnly factorCancer initiating cellsCancer-initiating cellsLevels of CD44Axillary surgeryLN positivityNode positivityPatient agePositive patientsClinicopathologic data
2011
P1-01-15: Do Serum Cytokines Predict Breast Cancer Behavior?
Lush E, Dedert E, Daup M, Dhabhar F, Spiegel D, Tillie J, McMasters K, Sephton S, Chagpar A. P1-01-15: Do Serum Cytokines Predict Breast Cancer Behavior? Cancer Research 2011, 71: p1-01-15-p1-01-15. DOI: 10.1158/0008-5472.sabcs11-p1-01-15.Peer-Reviewed Original ResearchSerum cytokine levelsHormone receptor statusLymph node statusCytokine levelsReceptor statusTumor sizeBreast cancer behaviorSerum cytokinesNode statusCancer behaviorIFN-gamma serum levelsMedian patient ageMedian tumor sizeSerum IFN-gammaSerum inflammatory cytokinesProgesterone receptor statusRole of inflammationFinal pathologic resultsPresence of metastasesBreast cancer patientsBreast cancer developmentVariety of cytokinesCohort of interestLymphovascular invasionPatient age
2010
Non‐clamped partial nephrectomy: techniques and surgical outcomes
Smith GL, Kenney PA, Lee Y, Libertino JA. Non‐clamped partial nephrectomy: techniques and surgical outcomes. BJU International 2010, 107: 1054-1058. PMID: 21040369, DOI: 10.1111/j.1464-410x.2010.09798.x.Peer-Reviewed Original ResearchConceptsPartial nephrectomyVascular clampingGroup AGroup BSolitary kidneyRenal functionBlood lossOncological efficacyPercentage changeVon Hippel-Lindau diseaseFour-variable ModificationRenal vascular clampingMedian tumor sizeRate of complicationsRenal Disease equationGlomerular filtration rateSubset of patientsMedian percentage changeRate of recurrencePositive margin rateHippel-Lindau diseaseUnclamped groupPerioperative deathsPreoperative eGFRRetrospective reviewPartial nephrectomy for selected renal cortical tumours of ≥7 cm
Karellas M, O’Brien M, Jang T, Bernstein M, Russo P. Partial nephrectomy for selected renal cortical tumours of ≥7 cm. BJU International 2010, 106: 1484-1487. PMID: 20518765, PMCID: PMC4319322, DOI: 10.1111/j.1464-410x.2010.09405.x.Peer-Reviewed Original ResearchConceptsRenal cortical tumorsPartial nephrectomyCortical tumorsRenal unitsLarge tumorsPre-existing renal insufficiencyUse of PNConventional clear cell carcinomaAccepted surgical approachMedian tumor sizeGlomerular filtration rateInstitutional review board approvalClear cell carcinomaEffective tumor controlReview board approvalRenal insufficiencySolitary kidneyMetastatic diseaseMedian ageAppropriate tumorSurgical databaseTumor sizeCell carcinomaSurgical approachTumor controlClinicopathologic Analysis of Ampullary Neoplasms in 450 Patients: Implications for Surgical Strategy and Long-Term Prognosis
Winter JM, Cameron JL, Olino K, Herman JM, de Jong MC, Hruban RH, Wolfgang CL, Eckhauser F, Edil BH, Choti MA, Schulick RD, Pawlik TM. Clinicopathologic Analysis of Ampullary Neoplasms in 450 Patients: Implications for Surgical Strategy and Long-Term Prognosis. Journal Of Gastrointestinal Surgery 2010, 14: 379-387. PMID: 19911239, DOI: 10.1007/s11605-009-1080-7.Peer-Reviewed Original ResearchConceptsLymph node metastasisAmpullary neoplasmsNode metastasisSurgical resectionTumor sizeInvasive adenocarcinomaMicroscopic vessel invasionInitial surgical procedureMedian tumor sizeOutcomes of patientsPoor histologic gradeLong-term prognosisSingle-institution databaseRegional lymph nodesAmpulla of VaterEarly invasive adenocarcinomaDepth of invasionMethodsBetween 1970Metastatic diseaseRadical resectionAmpullary adenomasClinicopathologic factorsLymph nodesClinicopathologic analysisPerineural invasion
2009
Use Pre- and Intra-Operative Data To Predict Probability of Positive Non-Sentinel Lymph Nodes.
Chagpar A, Blumencranz P, Whitworth P, Deck K, Rosenberg A, Simmons R, Reintgen D, Beitsch P, Julian T, Saha S, Mamounas E, Giuliano A, Cook E, Wang S. Use Pre- and Intra-Operative Data To Predict Probability of Positive Non-Sentinel Lymph Nodes. Cancer Research 2009, 69: 302-302. DOI: 10.1158/0008-5472.sabcs-09-302.Peer-Reviewed Original ResearchAxillary node dissectionNon-SLN metastasisTumor sizeIntra-operative dataBLN AssayPositive SLNMedian numberLogistic regression modelsPositive non-sentinel lymph nodesSentinel lymph node-positive patientsCompletion axillary node dissectionFrozen sectionsLymph node-positive patientsNon-sentinel lymph nodesStepwise logistic regression modelFurther positive nodesNon-SLN statusMedian tumor sizeNode-positive patientsPositive rateTumor size dataSignificant predictorsCohort of interestNode dissectionPositive nodes
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply